<b>Conclusions:</b> In this real-world study, early, intensive polytherapy, targeting the distinct pathophysiological defects in T2D, is associated with significantly more favourable cardiorenal outcomes, compared to insulin and SU therapy. This evidence concerns the gene INS and type 2 diabetes mellitus.